Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease

Patients with inflammatory bowel disease (IBD) are frequently treated with immunosuppressive treatments that can affect serological responses to SARS-CoV-2 vaccination. On Sept 1, 2021, the Joint Committee on Vaccination and Immunisation recommended a third dose for immunosuppressed patients, with patients with IBD eligible after Nov 26, 2021.

Author list


Judith Wellens

Stephanie Brann

Alex Adams

Luke Marlow

James O Lindsay

Jack J Satsangi

Novel Coronavirus SARS-CoV-2


The Lancet - Gastroenterology & Hepatology